Clinical experience with PSMA-targeting positron emission tomography (PET), especially with [68Ga]Ga-PSMA-11 [7,8,9,10,11,12,13,14], in patients with recurrent prostate cancer show that lesions can be detected in almost all patients, in some cases with very low PSA levels. This evidence concerns the gene FOLH1 and prostate cancer.